User login
Enter your username and password here in order to log in on the website:
Please note: While some information will still be current in a year, other information may already be out of date in three months time. If you are in any doubt, please feel free to ask.
GLPG1837 Galapagos clinical trial
- Question
- Hello
A clinical trial with the CFTR protein potentiator GLPG1837 (Galapagos) has just started. Obviously this molecule is for patients carrying a class III mutation.
Is the clinical trial ongoing in France? When will results be available?
If compared to Kalydeco® could this new molecule present additional interest?
Thank you for our reply
- Answer
- Hello
Galapagos society runs two phase 2 trials regarding the evaluation of GLPG1837 for CF patients carrying a G551D or S1251N mutation (class III mutation):
• https://clinicaltrials.gov/ct2/show?term=GLPG1837&rank=2
• https://clinicaltrials.gov/ct2/show?term=GLPG1837&rank=3
The trials are not ongoing in France.
We have no idea regarding the publications of the results of these 2 trials.
Like Kalydeco®, GLPG1837 is a potentiator. GLPG1837 should increase the probability that the defective channel will be open and allow chloride ions pass through the channel pore.
Best regards,
Anna Ronayette
- 20.06.2016
